Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer.
clinical trial
immunotherapy
lay summary
neoadjuvant treatment
nivolumab
non–small cell lung cancer
plain language summary
presurgery treatment
Journal
Future oncology (London, England)
ISSN: 1744-8301
Titre abrégé: Future Oncol
Pays: England
ID NLM: 101256629
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
1
5
2023
pubmed:
24
2
2023
entrez:
23
2
2023
Statut:
ppublish
Résumé
In this article, we summarize results from the ongoing phase 3 CheckMate 816 clinical study that were published in Adults who had not previously taken medications to treat NSCLC and whose cancer could be removed with surgery were included in CheckMate 816. During this study, a computer randomly assigned the treatment each person would receive before surgery for NSCLC. In total, 179 people were randomly assigned to receive Researchers found that people who Results from CheckMate 816 support the benefit of using
Identifiants
pubmed: 36815433
doi: 10.2217/fon-2023-0007
doi:
Substances chimiques
Nivolumab
31YO63LBSN
Ipilimumab
0
Banques de données
ClinicalTrials.gov
['NCT02998528']
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM